Innovent Biologics Unveils Promising Preclinical Results for IBI3011 and IBI3034 at 2025 ACR Meeting

Reuters11-05

Innovent Biologics Unveils Promising Preclinical Results for IBI3011 and IBI3034 at 2025 ACR Meeting

Innovent Biologics Inc. announced the presentation of new preclinical study results for two investigational therapies, IBI3011 and IBI3034, at the 2025 American College of Rheumatology $(ACR)$ Annual Meeting. IBI3011 is a humanized monoclonal antibody targeting IL-1RAP, designed to inhibit inflammation driven by IL1α, IL1β, and IL36, and demonstrated efficacy in animal models of gout and arthritis as well as favorable pharmacokinetic and safety profiles in monkeys. A high-concentration formulation of IBI3011 has been developed to allow subcutaneous administration, and its IND application has been approved by China's National Medical Products Administration (NMPA) for acute gouty arthritis. IBI3034, a TACI/BCMA chimeric fusion protein, is currently undergoing IND-enabling studies for B cell-mediated autoimmune diseases. The results were showcased as poster presentations at the ACR 2025 conference.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN14968) on November 05, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581659799?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-05 08:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581659799","market":"nz","top_or_hot":-1,"title":"Innovent Biologics Unveils Promising Preclinical Results for IBI3011 and IBI3034 at 2025 ACR Meeting","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Innovent Biologics Unveils Promising Preclinical Results for IBI3011 and IBI3034 at 2025 ACR Meeting\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IVBIY\">Innovent Biologics Inc.</a> announced the presentation of new preclinical study results for two investigational therapies, IBI3011 and IBI3034, at the 2025 American College of Rheumatology <a href=\"https://laohu8.com/S/ACR\">$(ACR)$</a> Annual Meeting. IBI3011 is a humanized monoclonal antibody targeting IL-1RAP, designed to inhibit inflammation driven by IL1α, IL1β, and IL36, and demonstrated efficacy in animal models of gout and arthritis as well as favorable pharmacokinetic and safety profiles in monkeys. A high-concentration formulation of IBI3011 has been developed to allow subcutaneous administration, and its IND application has been approved by China's National Medical Products Administration (NMPA) for acute gouty arthritis. IBI3034, a TACI/BCMA chimeric fusion protein, is currently undergoing IND-enabling studies for B cell-mediated autoimmune diseases. The results were showcased as poster presentations at the ACR 2025 conference.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/IVBXF\">Innovent Biologics Inc.</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: CN14968) on November 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Innovent Biologics Unveils Promising Preclinical Results for IBI3011 and IBI3034 at 2025 ACR Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInnovent Biologics Unveils Promising Preclinical Results for IBI3011 and IBI3034 at 2025 ACR Meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-05 08:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Innovent Biologics Unveils Promising Preclinical Results for IBI3011 and IBI3034 at 2025 ACR Meeting\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IVBIY\">Innovent Biologics Inc.</a> announced the presentation of new preclinical study results for two investigational therapies, IBI3011 and IBI3034, at the 2025 American College of Rheumatology <a href=\"https://laohu8.com/S/ACR\">$(ACR)$</a> Annual Meeting. IBI3011 is a humanized monoclonal antibody targeting IL-1RAP, designed to inhibit inflammation driven by IL1α, IL1β, and IL36, and demonstrated efficacy in animal models of gout and arthritis as well as favorable pharmacokinetic and safety profiles in monkeys. A high-concentration formulation of IBI3011 has been developed to allow subcutaneous administration, and its IND application has been approved by China's National Medical Products Administration (NMPA) for acute gouty arthritis. IBI3034, a TACI/BCMA chimeric fusion protein, is currently undergoing IND-enabling studies for B cell-mediated autoimmune diseases. The results were showcased as poster presentations at the ACR 2025 conference.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/IVBXF\">Innovent Biologics Inc.</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: CN14968) on November 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2097828631.EUR","symbol_name":"AZ EQUITY CHINA \"A\" (EUR) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDL3TBBFX:1","article_id":"2581659799","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581659799","pubTimestamp":1762300845,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Innovent Biologics Inc. announced the presentation of new preclinical study results for two investigational therapies, IBI3011 and IBI3034, at the 2025 American College of Rheumatology  Annual Meeting. IBI3011 is a humanized monoclonal antibody targeting IL-1RAP, designed to inhibit inflammation driven by IL1α, IL1β, and IL36, and demonstrated efficacy in animal models of gout and arthritis as well as favorable pharmacokinetic and safety profiles in monkeys. A high-concentration formulation of IBI3011 has been developed to allow subcutaneous administration, and its IND application has been approved by China's National Medical Products Administration  for acute gouty arthritis. IBI3034, a TACI/BCMA chimeric fusion protein, is currently undergoing IND-enabling studies for B cell-mediated autoimmune diseases. The results were showcased as poster presentations at the ACR 2025 conference.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","BK1161":"生物科技","LU0502904849.HKD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (HKD) ACC","BK1147":"投资银行业与经纪业","01911":"华兴资本控股","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","01801":"信达生物","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU0455707207.USD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (USD) INC","BK1589":"北水核心资产","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","BK1583":"高瓴概念","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD"},"translate_title":"信达生物在2025年ACR会议上公布IBI3011和IBI3034有希望的临床前结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01911":0.9,"01801":0.9},"content_text":"Innovent Biologics Unveils Promising Preclinical Results for IBI3011 and IBI3034 at 2025 ACR Meeting\n    \n\nInnovent Biologics Inc. announced the presentation of new preclinical study results for two investigational therapies, IBI3011 and IBI3034, at the 2025 American College of Rheumatology $(ACR)$ Annual Meeting. IBI3011 is a humanized monoclonal antibody targeting IL-1RAP, designed to inhibit inflammation driven by IL1α, IL1β, and IL36, and demonstrated efficacy in animal models of gout and arthritis as well as favorable pharmacokinetic and safety profiles in monkeys. A high-concentration formulation of IBI3011 has been developed to allow subcutaneous administration, and its IND application has been approved by China's National Medical Products Administration (NMPA) for acute gouty arthritis. IBI3034, a TACI/BCMA chimeric fusion protein, is currently undergoing IND-enabling studies for B cell-mediated autoimmune diseases. The results were showcased as poster presentations at the ACR 2025 conference.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN14968) on November 05, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581659799","isCrawlerRequest":true}